Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor α in the development of bleomycin-induced lung injury

Shock

Volumn 24, Issue 6, 2006, Pages 547-555

  Genovese, Tiziana ^a   Mazzon, Emanuela ^a   Di Paola, Rosanna ^a   Muià, Carmelo ^a   Crisafulli, Concetta ^a   Caputi, Achille P ^a   Cuzzocrea, Salvatore ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Bleomycin; Cytokines; Inflammation; Lung injury; Neutrophil infiltration; Signal transduction

Indexed keywords

BLEOMYCIN; CELL NUCLEUS RECEPTOR; INTERLEUKIN 1BETA; LIGAND; MYELOPEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; POLY(ADENOSINE DIPHOSPHATE RIBOSE); RETINOIC ACID RECEPTOR; STEROID RECEPTOR; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC ANTIBIOTIC; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; ENZYME ACTIVITY; GENE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNOCKOUT MOUSE; LUNG INJURY; MORTALITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PPAR ALPHA GENE; PROTEIN FAMILY; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG POTENTIATION; HUMAN; INJURY; LUNG; METABOLISM; MOUSE MUTANT; PATHOLOGY; PNEUMONIA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; HUMANS; LIGANDS; LUNG; MICE; MICE, KNOCKOUT; PEROXISOME PROLIFERATORS; PNEUMONIA; PPAR ALPHA; PYRIMIDINES;

EID: 33646799831     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000190825.28783.a4     Document Type: Article

References (46)

1. Krishna G, Liu K, Shigemitsu H, Gao M, Raffin TA, Rosen GD: PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis. Am J Pathol 158:997-1004, 2001.
2. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161:646-664, 2000.
3. Mapel DW, Samet JM, Coultas DB: Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest 110:1058-1067, 1996.
4. Douglas WW, Ryu JH, Bjoraker JA, Schroeder DR, Myers JL, Tazelaar HD, Swensen SJ, Scanlon PD, Peters SG, DeRemee RA: Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 72:201-209, 1997.
5. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, Hutchinson J, Pardee NE, Winterbauer RH: Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144:291-296, 1991.
6. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M: Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low-dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 44:280-288, 1989.
7. Peters-Golden M, Bailie M, Marshall T, Wilke C, Phan SH, Toews GB, Moore BB: Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 165:229-235, 2002.
8. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240:889-895, 1988.
9. Murphy GJ, Holder JC: PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21:469-474, 2000.
10. Wayman N, McDonald MC, Thompson AS, Threadgill MD, Thiemermann C: 5-Amino isoquinolinone, a potent inhibitor of poly (adenosine 5′-diphosphate ribose) polymerase, reduces myocardial infarct size. Eur J Pharmacol 430:93-100, 2001.
11. Sher T, Yi HF, Gonzalez FJ: cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32:5598-5604, 1993.
12. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, Mirabile RC, Aravindhan K, Ohlstein EH: Activation of peroxisome proliferator-activated receptor-α protects the heart from ischemia/reperfusion injury. Circulation 108:2393-2399, 2003.
13. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, Caputi AP: WY 14643, a potent exogenous PPAR-α ligand, reduces intestinal injury associated with splanchnic artery occlusion shock. Shock 22:340-346, 2004.
14. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, Centorrino T, Caputi AP: Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor α (PPAR-α) in the development of inflammatory bowel disease in mice. Lab Invest 84:1643-1654, 2004.
15. Spiegelman BM: PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998.
16. Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KW, Mossakowska D, Murphy GJ, Roxbee Cox L, Smith SA: Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J Pharmacol Exp Ther 284:751-759, 1998.
17. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550, 2000.
18. 2 on bleomycin-induced lung injury. Eur Respir J 25:1-9, 2005.
19. Ashcroft T, Simpson JM, Timbrell V: Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41:467-470, 1988.
20. Schutte B, Nuydens R, Geerts H, Ramaekers F: Annexin V binding assay as a tool to measure apoptosis in differentiated neuronal cells. J Neurosci Methods 86:63-69, 1998.
21. Mullane KM, Kraemer R, Smith B: Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 14:157-167, 1985.
22. Diaz-Granados N, Howe K, Lu J, McKay DM: Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 156:2169-2177, 2000.
23. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T: Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκ B-C/EBP-β complex formation. Blood 101:545-551, 2003.
24. Gervois P, Vu-Dac N, Kleemann R, Kockx M, Dubois G, Laine B, Kosykh V, Fruchart JC, Kooistra T, Staels B: Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein β. J Biol Chem 276:33471-33477, 2001.
25. Izumi T, Saito Y, Kishimoto I, Harada M, Kuwahara K, Hamanaka I, Takahashi N, Kawakami R, Li Y, Takemura G, Fujiwara H, Garbers DL, Mochizuki S, Nakao K: Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-κB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest 108:203-213, 2001.
26. Pan LH, Ohtani H, Yamauchi K, Nagura H: Coexpression of TNFα and IL-1β in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathol Int 46:91-99, 1996.
27. Goldstein RH, Fine A: Potential therapeutic initiatives for fibrogenic lung diseases. Chest 108:848-855, 1995.
28. Chatham WW, Swaim R, Frohsin H Jr, Heck LW, Miller EJ, Blackburn WD Jr: Degradation of human articular cartilage by neutrophils in synovial fluid. Arthritis Rheum 36:51-58, 1993.
29. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD: Isolation of the human peroxisome proliferator-activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 4:281-299, 1995.
30. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, Caputi AP: WY 14643, a potent exogenous PPAR-α ligand, reduces intestinal injury associated with splanchnic artery occlusion shock. Shock 22:340-346, 2004.
31. Szabó C, Lim LHK, Cuzzocrea S, Getting SJ, Zingarelli B, Flower RJ, Salzman AL, Perretti M: Inhibition of poly (ADP-ribose) synthetase exerts anti-inflammatory effects and inhibits neutrophil recruitment. J Exp Med 186:1041-1049, 1997.
32. Szabó C, Viràg L, Cuzzocrea S, Scott GS, Hake P, O'Connor MP, Zingarelli B, Salzman A, Kun E: Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly (ADP-ribose) synthetase. Proc Natl Acad Sci USA 9:3867-3872, 1998.
33. Marber MS, Latchman DS, Walker JM, Yellon DM: Cardiac stress protein elevation 24 hours after brief ischaemia or heat stress is associated with resistance to myocardial infarction. Circulation 88:1264-1272, 1993.
34. Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ, Motterlini R: Hemeoxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am J Physiol 278:H643-H651, 2000.
35. Lin KT, Xue JY, Nomen M, Spur B, Wong PY: Peroxynitrite-induced apoptosis in HL-60 cells. J Biol Chem 94:16487-16490, 1995.
36. Szabo C, Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL: Endothelial dysfunction in endotoxic shock: importance of the activation of poly (ADP ribose) synthetase (PARS) by peroxynitrite. J Clin Invest 94:723-735, 1997.
37. Virag L, Scott GS, Cuzzocrea S, Marmer D, Salzman AL, Szabo C: Peroxynitrite-induced thymocyte apoptosis: the role of caspases and poly (ADP-ribose) synthetase (PARS) activation. Immunology 94:345-355, 1998.
38. Leist M, Volbracht C, Kuhnle S, Fava E, Ferrando-May E, Nicotera P: Caspase-mediated apoptosis in neuronal excitotoxicity triggered by nitric oxide. Mol Med 3:750-764, 1997.
39. Li X, Rayford H, Uhal BD: Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am J Pathol 163:2523-2530, 2003.
40. Hagimoto N, Kuwano K, Nomoto Y, Kunitake R, Hara N: Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 16:91-101, 1997.
41. Kuwano K, Kunitake R, Maeyama T, Hagimoto N, Kawasaki M, Matsuba T, Yoshimi M, Inoshima I, Yoshida K, Hara N: Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 280:L316-L325, 2001.
42. Bishop-Bailey D, Hla T: Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-δ12, 14-prostaglandin J2. J Biol Chem 274:17042-17048, 1999.
43. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B: Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273:25573-25580, 1998.
44. Roberts RA, James NH, Woodyatt NJ, Macdonald N, Tugwood JD: Evidence for the suppression of apoptosis by the peroxisome proliferator-activated receptor α (PPAR α). Carcinogenesis 19:43-48, 1998.
45. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393:790-793, 1998.
46. Inoue I, Hayashi K, Yagasaki F, Nakamura K, Matsunaga T, Xu H, Inukai K, Awata T, Komoda T, Katayama S: Apoptosis of endothelial cells may be mediated by genes of peroxisome proliferator-activated receptor γ1 (PPARγ1) and PPARα genes. J Atheroscler Thromb 10:99-108, 2003.